About Pudee

Reliability, Responsibility and Rapidity

Founded in 2007, focus on the synthesis of small molecule compounds and the extraction of some natural compounds. We develop, produce and sell high-quality advanced intermediates and some APIs with competitive prices.
Get Appointment

Contact Info

  • Building 2, Handa Science and Technology Park
    No. 8 Pioneer Road
    High-tech Zone. Suzhou.
  • 86 512 6803 2792
    86 512 6803 2791
  • willdyhan@pudeepharm.com
    sales@pudeepharm.com

Product Details

Ribociclib intermediate 1

Ribociclib intermediate 1 | 1374639-78-7

Chemical Name: 4-(6-(7-cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)pyridin-3-yl)piperazine-1-carboxylate

CAS Number: 1374639-78-7
Formula: C28H38N8O3
Molecular weight: 534.65

Product Description

"

Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.

Ribociclib was approved by the US FDA in March 2017 and the European Medicines Agency in August 2017 for use in combination with an aromatase inhibitor (such as letrozole) to treat HR-positive, HER2-negative advanced or metastatic breast cancers.

In the clinical trial relevant for the drug's approval, ribociclib significantly improved progression-free survival (PFS), that is, the time span the cancer did not get worse.

One of intermediates of Ribociclib, the appearance is light-yellow solid, the purity is not less than 98% by HPLC.

"